Wall Street analysts predict that Atara Biotherapeutics Inc (NASDAQ:ATRA) will post ($1.18) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Atara Biotherapeutics’ earnings, with estimates ranging from ($1.18) to ($1.17). Atara Biotherapeutics posted earnings per share of ($1.02) during the same quarter last year, which indicates a negative year over year growth rate of 15.7%. The business is expected to report its next earnings results on Thursday, November 8th.
On average, analysts expect that Atara Biotherapeutics will report full year earnings of ($4.58) per share for the current financial year, with EPS estimates ranging from ($4.59) to ($4.58). For the next financial year, analysts expect that the company will report earnings of ($5.12) per share, with EPS estimates ranging from ($5.19) to ($5.05). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Atara Biotherapeutics.
Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Wednesday, August 1st. The biotechnology company reported ($1.15) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.98) by ($0.17).
ATRA stock traded down $2.38 during midday trading on Friday, reaching $35.77. 9,642 shares of the company’s stock traded hands, compared to its average volume of 716,928. Atara Biotherapeutics has a 1-year low of $12.65 and a 1-year high of $54.45. The stock has a market capitalization of $1.87 billion, a price-to-earnings ratio of -9.40 and a beta of 2.54.
In other Atara Biotherapeutics news, EVP Christopher Haqq sold 775 shares of the stock in a transaction on Wednesday, August 15th. The stock was sold at an average price of $37.54, for a total value of $29,093.50. Following the transaction, the executive vice president now directly owns 331,355 shares in the company, valued at approximately $12,439,066.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Joe Newell sold 10,000 shares of the stock in a transaction on Monday, July 30th. The shares were sold at an average price of $35.78, for a total value of $357,800.00. Following the completion of the transaction, the insider now owns 41,858 shares in the company, valued at $1,497,679.24. The disclosure for this sale can be found here. Insiders have sold a total of 93,575 shares of company stock valued at $3,633,158 over the last ninety days. Insiders own 10.60% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in ATRA. BlackRock Inc. boosted its position in Atara Biotherapeutics by 45.0% in the 1st quarter. BlackRock Inc. now owns 2,844,441 shares of the biotechnology company’s stock valued at $110,934,000 after buying an additional 882,180 shares during the last quarter. PointState Capital LP bought a new position in Atara Biotherapeutics in the 1st quarter valued at $11,583,000. Northern Trust Corp boosted its position in Atara Biotherapeutics by 27.1% in the 2nd quarter. Northern Trust Corp now owns 497,371 shares of the biotechnology company’s stock valued at $18,278,000 after buying an additional 105,935 shares during the last quarter. UBS Group AG boosted its position in Atara Biotherapeutics by 7,970.1% in the 1st quarter. UBS Group AG now owns 102,974 shares of the biotechnology company’s stock valued at $4,016,000 after buying an additional 101,698 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its position in Atara Biotherapeutics by 73.2% in the 2nd quarter. Assenagon Asset Management S.A. now owns 237,668 shares of the biotechnology company’s stock valued at $8,734,000 after buying an additional 100,432 shares during the last quarter.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.